|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Mon 5/6
|
|
Download |
|
|
|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
N/A |
Shares
Out: |
239,210,000 |
Market
Cap: |
478.42(K) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.000001 - $0.0721 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Amyris is a biotechnology company. Co. creates, manufactures and commercializes consumer products and ingredients. Co.'s ingredients and consumer products are powered by its fermentation-based Lab-to-Market technology platform. Co. has produced a renewable farnesene brand, Biofene®, a long-chain, branched hydrocarbon molecule that Co. manufactures through fermentation using engineered microbes. Co. has formulated its fermentation-based ingredients such as Squalane, Hemisqualane, and Steviol Glycoside Rebaudioside M into its consumer brands. Co.'s consumer brands include: Biossance® clean beauty skincare, Pipette® clean baby skincare, and Purecane sweetener.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
252,367 |
Total Sell Value |
$0 |
$0 |
$0 |
$304,254 |
Total People Sold |
0 |
0 |
0 |
2 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Valiasek Kathleen |
Chief Financial Officer |
|
2019-05-01 |
4 |
D |
$4.05 |
$95,540 |
D/D |
(23,590) |
226,523 |
|
- |
|
Cherry Joel |
President of R&D |
|
2019-05-01 |
4 |
D |
$4.05 |
$116,964 |
D/D |
(28,880) |
241,417 |
|
- |
|
Kung Frank |
Director |
|
2019-04-29 |
4 |
B |
$4.76 |
$4,348,398 |
I/I |
913,529 |
787,259 |
2.1 |
- |
|
Doerr L John |
Director |
|
2019-04-24 |
4 |
B |
$5.12 |
$14,502,093 |
I/I |
2,832,440 |
17,417,584 |
2.25 |
- |
|
Doerr L John |
Director |
|
2019-04-15 |
4 |
B |
$2.87 |
$19,321,899 |
I/I |
6,732,369 |
14,585,144 |
2.25 |
- |
|
Melo John |
President and CEO |
|
2019-01-14 |
4 |
A |
$0.00 |
$0 |
D/D |
38,616 |
781,868 |
|
- |
|
Valiasek Kathleen |
Chief Financial Officer |
|
2019-01-02 |
4 |
D |
$3.34 |
$5,067 |
D/D |
(1,517) |
250,113 |
|
- |
|
Alvarez Eduardo |
Chief Operating Officer |
|
2018-12-13 |
4 |
B |
$4.23 |
$50,058 |
D/D |
11,834 |
333,876 |
2.74 |
- |
|
Valiasek Kathleen |
Chief Financial Officer |
|
2018-11-27 |
4 |
B |
$4.37 |
$100,574 |
D/D |
23,000 |
251,630 |
2.74 |
- |
|
Koninklijke Dsm N.v. |
|
|
2018-11-19 |
4 |
OE |
$0.00 |
$1,619 |
I/I |
2,678,402 |
13,007,353 |
|
- |
|
Koninklijke Dsm N.v. |
|
|
2018-11-19 |
4 |
A |
$0.00 |
$0 |
I/I |
1,643,991 |
10,328,951 |
|
- |
|
Total Raffinage Chimie |
Director by Deputization |
|
2018-11-08 |
4 |
OE |
$4.40 |
$9,794,862 |
D/D |
2,226,105 |
9,953,472 |
|
- |
|
Kung Frank |
Director |
|
2018-11-01 |
4 |
A |
$0.00 |
$0 |
I/I |
667 |
667 |
|
- |
|
Kung Frank |
Director |
|
2018-11-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(667) |
3,599 |
|
- |
|
Melo John |
President and CEO |
|
2018-11-01 |
4 |
D |
$7.53 |
$3,471 |
D/D |
(461) |
743,252 |
|
- |
|
Cherry Joel |
President of R&D |
|
2018-11-01 |
4 |
D |
$7.53 |
$4,292 |
D/D |
(570) |
269,583 |
|
- |
|
Total Raffinage Chimie |
Director by Deputization |
|
2018-10-16 |
4 |
OE |
$4.40 |
$15,174,812 |
D/D |
3,448,821 |
7,727,367 |
|
- |
|
Melo John |
President and CEO |
|
2018-10-15 |
4 |
AS |
$7.50 |
$38,952 |
D/D |
(5,195) |
743,713 |
|
- |
|
Alvarez Eduardo |
Chief Operating Officer |
|
2018-10-01 |
4 |
D |
$7.49 |
$73,664 |
D/D |
(9,835) |
322,042 |
|
- |
|
Alvarez Eduardo |
Chief Operating Officer |
|
2018-09-05 |
4 |
B |
$8.45 |
$100,326 |
D/D |
11,877 |
331,877 |
2.74 |
- |
|
Valiasek Kathleen |
Chief Financial Officer |
|
2018-08-22 |
4 |
B |
$7.20 |
$100,800 |
D/D |
14,000 |
228,630 |
2.74 |
- |
|
Kung Frank |
Director |
|
2018-08-20 |
4 |
OE |
$4.40 |
$7,175,758 |
I/I |
1,630,854 |
676,448 |
|
- |
|
Kung Frank |
Director |
|
2018-08-20 |
4 |
S |
$6.22 |
$7,139,941 |
I/I |
(1,148,122) |
478,571 |
|
- |
|
Kung Frank |
Director |
|
2018-08-17 |
4 |
OE |
$4.26 |
$22,032,979 |
I/I |
5,042,437 |
617,877 |
|
- |
|
Kung Frank |
Director |
|
2018-08-17 |
4 |
S |
$6.22 |
$17,268,128 |
I/I |
(2,776,762) |
139,306 |
|
- |
|
406 Records found
|
|
Page 7 of 17 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|